ReviewBJR open2025
Progressive pulmonary fibrosis: current perspectives in diagnostic imaging.
Review in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A subset of patients with interstitial lung diseases (ILDs) experiences disease progression despite standard treatment protocols. Similar to idiopathic pulmonary fibrosis, the archetype of progressive fibrotic ILDs, these patients exhibit worsening clinical symptoms, declining lung function, and progressive radiological changes, often resulting in shortened survival. This progressive disease pattern is classified under the term progressive pulmonary fibrosis or progressive fibrosing ILD. Radiological imaging, particularly high-resolution computed tomography (HRCT), is integral to diagnosing ILDs and plays a critical role within multidisciplinary ILD boards. HRCT is instrumental in identifying patients at a higher risk for disease progression and may provide valuable prognostic insights. Additionally, serial imaging is essential for detecting progression over time. While visual assessment remains the primary method for evaluating disease advancement, emerging quantitative techniques, including those utilizing machine learning, are currently undergoing validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.